The last decade was noted for the emergence and prevalence of antimicrobial agent-resistant pneumococci. Strains resistant to macrolides, chloramphenicol, and tetracycline have been registered in a number of countries (1). In some regions, resistance to macrolides prevails over the resistance to penicillin. Macrolide resistance has been reported to be high among pneumococci in Asian countries (4), but the distribution of these macrolide resistance determinants is not known.
Of the isolates expressing the MLS B phenotype, only the ermB gene was detected in 86.63% (13 strains of 15) of the isolates by PCR. Two isolates were repeatedly negative on testing for ermB but were positive for ermA gene. All the isolates expressing the M phenotype were positive for the mefE gene by PCR. The majority of the M-phenotype strains (84.37%, or 27 of 32) had constitutive resistance (cML phenotype); only 15.625% of these strains had inducible resistance (iML phenotype).
Before 2000, it was recorded (5) that among the erythromycin-resistant S. pneumoniae isolates, the majority (78%) had an ML phenotype and 22% had an M phenotype. All S. pneumoniae isolates exhibiting a cML or iML phenotype harbored the ermB gene.
Thus, the study indicated a high percentage of erythromycin resistance among clinical isolates of S. pneumoniae in the Far East of Russia; this fact requires a more careful approach to diagnostics of macrolide resistance in pneumococci in the clinical microbiology laboratory, particularly in areas with high rates of macrolide resistance.
